Clinical radioimmunotherapy--the role of radiobiology
- PMID: 22064461
- DOI: 10.1038/nrclinonc.2011.160
Clinical radioimmunotherapy--the role of radiobiology
Abstract
Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors. Radioimmunotherapy involves the administration of radiolabeled monoclonal antibodies that are directed specifically against tumor-associated antigens or against the tumor microenvironment. Although many tumor-associated antigens have been identified as possible targets for radioimmunotherapy of patients with hematological or solid tumors, clinical success has so far been achieved mostly with radiolabeled antibodies against CD20 ((131)I-tositumomab and (90)Y-ibritumomab tiuxetan) for the treatment of lymphoma. In this Review, we provide an update on the current challenges aimed to improve the efficacy of radioimmunotherapy and discuss the main radiobiological issues associated with clinical radioimmunotherapy.
Similar articles
-
General overview of radioimmunotherapy of solid tumors.Immunotherapy. 2013 May;5(5):467-87. doi: 10.2217/imt.13.34. Immunotherapy. 2013. PMID: 23638743 Review.
-
Radioimmunotherapy of solid tumors: searching for the right target.Curr Drug Deliv. 2011 Jan;8(1):26-44. doi: 10.2174/156720111793663651. Curr Drug Deliv. 2011. PMID: 21034423 Free PMC article. Review.
-
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).Semin Oncol. 2003 Dec;30(6 Suppl 17):6-10. doi: 10.1053/j.seminoncol.2003.10.005. Semin Oncol. 2003. PMID: 14710397 Review.
-
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.J Nucl Med. 2007 Nov;48(11):1767-76. doi: 10.2967/jnumed.107.043489. Epub 2007 Oct 17. J Nucl Med. 2007. PMID: 17942813
-
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. Drugs Today (Barc). 2004. PMID: 15045033 Review.
Cited by
-
Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy.J Nanobiotechnology. 2024 Jun 2;22(1):306. doi: 10.1186/s12951-024-02520-6. J Nanobiotechnology. 2024. PMID: 38825717 Free PMC article.
-
Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.Research (Wash D C). 2023 Nov 28;6:0282. doi: 10.34133/research.0282. eCollection 2023. Research (Wash D C). 2023. PMID: 38706713 Free PMC article.
-
Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.ACS Appl Bio Mater. 2024 Feb 19;7(2):1240-1249. doi: 10.1021/acsabm.3c01158. Epub 2024 Feb 7. ACS Appl Bio Mater. 2024. PMID: 38323544 Free PMC article.
-
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy.Mol Biol Rep. 2024 Jan 28;51(1):219. doi: 10.1007/s11033-023-09096-8. Mol Biol Rep. 2024. PMID: 38281269 Free PMC article. Review.
-
Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.Int J Mol Sci. 2024 Jan 4;25(1):664. doi: 10.3390/ijms25010664. Int J Mol Sci. 2024. PMID: 38203834 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources